Drug Profile
Erythropoietin biosimilar - Curaxys
Latest Information Update: 30 Oct 2021
Price :
$50
*
At a glance
- Originator Curaxys
- Developer Curaxys; University of Cadiz
- Class Antianaemics; Erythropoietins
- Mechanism of Action Erythropoiesis stimulants; Erythropoietin receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Anaemia
Most Recent Events
- 24 Jun 2015 Discontinued for Anaemia in Spain (SC)